| Literature DB >> 27579153 |
Yu-Chiang Hung1, Tai-Long Pan2, Wen-Long Hu3.
Abstract
Cancer is a leading cause of death worldwide. We aim to provide a systematic review about the roles of reactive oxygen species (ROS) in anticancer therapy with Salvia miltiorrhiza Bunge (Danshen). Danshen, including its lipophilic and hydrophilic constituents, is potentially beneficial for treating various cancers. The mechanisms of ROS-related anticancer effects of Danshen vary depending on the specific type of cancer cells involved. Danshen may enhance TNF-α-induced apoptosis, upregulate caspase-3, caspase-8, caspase-9, endoplasmic reticulum stress, P21, P53, Bax/Bcl-2, DR5, and AMP-activated protein kinase, or activate the p38/JNK, mitogen-activated protein kinase, and FasL signaling pathways. Conversely, Danshen may downregulate human telomerase reverse transcriptase mRNA, telomerase, survivin, vascular endothelial growth factor/vascular endothelial growth factor receptor 2, CD31, NF-κB, Erk1/2, matrix metalloproteinases, microtubule assembly, and receptor tyrosine kinases including epidermal growth factor receptors, HER2, and P-glycoprotein and inhibit the PI3K/Akt/mTOR or estrogen receptor signaling pathways. Therefore, Danshen may inhibit cancer cells proliferation through antioxidation on tumor initiation and induce apoptosis or autophagy through ROS generation on tumor progression, tumor promotion, and tumor metastasis. Based on the available evidence regarding its anticancer properties, this review provides new insights for further anticancer research or clinical trials with Danshen.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27579153 PMCID: PMC4989081 DOI: 10.1155/2016/5293284
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Chemical structures of the different constituents of Danshen. Danshen contains lipophilic compounds including tanshinone I, tanshinone IIA, acetyltanshinone IIA, cryptotanshinone, isocryptotanshinone, dihydrotanshinone, and miltirone. Danshen also contains hydrophilic phenolic acids including salvianolic acids A and B.
Lipophilic components from Salvia miltiorrhiza that modify ROS-related effects on cancer cells.
| Components [reference] | Cancer cells | Effects |
|---|---|---|
| Tanshinones [ | Lung cancer 95D cells | Induces apoptosis and prosurvival autophagy mediated by increasing the formation of intracellular ROS |
|
| ||
| Tanshinone I [ | Prostate cancer cells | Enhances TRAIL via upregulation of miR-135a-3p-mediated death receptor 5 |
|
| ||
| Tanshinone I [ | Human breast cancer MDA-MB-453 cells | Induces antiproliferative activity and cell cycle arrest by inhibiting the PI3K/Akt/mTOR signaling pathways |
|
| ||
| Tanshinone I [ | Leukemia U937 THP-1 and SHI 1 cells | Induces apoptosis by activating caspase-3 and decreasing hTERT mRNA expression and telomerase activity, as well as downregulating survivin expression |
|
| ||
| Tanshinone IIA [ | Prostate cancer cells | Induces apoptosis and autophagy that depends on intracellular ROS production |
|
| ||
| Tanshinone IIA [ | Gastric cancer cells | Suppresses cell growth by blocking glucose metabolism |
|
| ||
| Tanshinone IIA [ | Human non-small cell lung cancer A549 cells | Decreases VEGF/VEGFR2 expression and induces apoptosis and cell cycle arrest at the S phase |
|
| ||
| Tanshinone IIA [ | Human oral cancer KB cells | Induces apoptosis through the mitochondria-dependent pathway in which there is a loss of the mitochondrial membrane potential and activation of caspase-3 and caspase-9 |
|
| ||
| Tanshinone IIA [ | Human colon cancer cells | UDP-glucuronosyltransferase 1A compromises the intracellular accumulation and resultant apoptotic effect of tanshinone IIA |
|
| ||
| Tanshinone IIA [ | Cervical cancer CaSki cells | Inhibits cell growth by activating ER stress pathways and promoting caspase cascades with concomitant upregulation of p38 and JNK phosphorylation and signaling |
|
| ||
| Tanshinone IIA [ | Human hepatoma J5 cells | Increases Bax and caspase-3 and decreases CD31 expression |
|
| ||
| Tanshinone IIA [ | Non-small cell lung cancer H596 cells | Activates ROS-triggered, p53-independent, and caspase-dependent mitochondrial apoptotic cell death pathway |
|
| ||
| Tanshinone IIA [ | 786-O human renal cell carcinoma cells | Induces apoptosis by activating p53 expression and subsequently upregulating p21 and Bax |
|
| ||
| Tanshinone IIA [ | Leukemia U937 cells | Induces apoptosis by activating PXR, which suppresses the activity of NF- |
|
| ||
| Tanshinone IIA [ | human non-small lung cancer A549 cells | Induces apoptosis by increasing ROS and the ratio of Bax/Bcl-2 and then decreasing the mitochondrial membrane potential, which leads to cytochrome c release |
|
| ||
| Tanshinone IIA [ | Small cell lung cancer H146 cells | Inhibits cell growth by upregulating the Bax/Bcl-2 ratio and decreasing the mitochondrial membrane potential |
|
| ||
| Tanshinone IIA [ | Cervical cancer HeLa cells | Inhibits cell growth by interfering with the process of microtubule assembly, leading to G2/M phase arrest and subsequent apoptosis |
|
| ||
| Acetyltanshinone IIA [ | Breast cancer | Induces G1/S phase arrest and apoptosis by downregulating the receptor tyrosine kinases EGFR/HER2 and activating AMP-activated protein kinase |
|
| ||
| Acetyltanshinone IIA [ | Breast cancer cells | Induces ROS generation and Bax translocation to mitochondria, resulting in mitochondrial damage, cytochrome c release, caspase-3 activation, and apoptotic cell death |
|
| ||
| Cryptotanshinone [ | Breast cancer cells | Suppresses estrogen receptor signaling |
|
| ||
| Cryptotanshinone [ | Acute lymphoblastic leukemia cells | Inhibits cellular movement and induces G2/M cell cycle arrest and apoptosis |
|
| ||
| Cryptotanshinone [ | Lung cancer cells | Induces prodeath autophagy through JNK signaling that is mediated by ROS generation |
|
| ||
| Cryptotanshinone [ | HepG2 hepatoma | Induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signaling pathway |
|
| ||
| Cryptotanshinone [ | A375 melanoma cells | Restores sensitivity in cancer cells that are resistant to TRAIL by upregulating DR5 expression |
|
| ||
| Cryptotanshinone [ | Rh30 human rhabdomyosarcoma; DU145 prostate carcinoma; and human MCF-7 breast cancer cells | Induces ROS, thereby activating p38/JNK and inhibiting Erk1/2 leading to caspase-independent cell death |
|
| ||
| Cryptotanshinone [ | Neuro-2a cells | Inhibits sodium nitroprusside-induced apoptosis by antioxidant effects and regulating the NF- |
|
| ||
| Cryptotanshinone [ | HepG2 hepatoma and MCF-7 breast cancer cells | Induces ER stress-mediated apoptosis |
|
| ||
| Cryptotanshinone [ | Prostate cancer cells | Suppresses androgen receptor- (AR-) mediated growth by blocking AR dimerization and formation of the AR-coregulator complex |
|
| ||
| Cryptotanshinone [ | Chronic myeloid leukemia KBM-5 cells | Enhances TNF- |
|
| ||
| Isocryptotanshinone [ | Human breast cancer MCF-7 cells | Induces apoptosis and activates MAPK signaling pathways |
|
| ||
| Dihydrotanshinone [ | HepG2 cells | Activates ROS-mediated phosphorylation of p38 MAPK |
|
| ||
| Dihydrotanshinone I [ | Colon cancer | Induces caspase- and ROS-dependent apoptosis and autophagy |
|
| ||
| 15,16-Dihydrotanshinone I [ | Human HL-60 Leukemia Cells | Induces apoptosis through activation of the JNK and FasL signaling pathways |
|
| ||
| Miltirone [ | Human hepatoma HepG2 cells | Activates caspase-dependent apoptotic pathways and triggers ROS-mediated MAPK signaling pathways |
|
| ||
| Miltirone [ | Acute lymphoblastic leukemia cells | Induces G2/M cell cycle arrest and apoptosis |
Hydrophilic components from Salvia miltiorrhiza that modify ROS-related effects on cancer cells.
| Components [reference] | Cancer cells | Effects |
|---|---|---|
| Salvianolic acid A [ | MCF-7 breast cancer cells | Downregulates the level of P-glycoprotein and triggers apoptosis, which is associated with increased caspase-3 activity, disrupted mitochondrial membrane potential, downregulated Bcl-2 expression, and upregulated Bax expression in resistant cells |
|
| ||
| Salvianolic acid A [ | Human neuroblastoma SH-SY5Y cells | Prevents 1-methyl-4-phenylpyridinium ion-induced cytotoxicity, which may be ascribed to its antioxidant properties and antiapoptotic activity via regulating the expression of Bcl-2 and Bax |
|
| ||
| Salvianolic acid B [ | Human glioma U87 cells | Induces apoptosis through p38-mediated ROS generation |
|
| ||
| Salvianolic acid B [ | Human neuroblastoma SH-SY5Y cells | Prevents 1-methyl-4-phenylpyridinium-induced apoptosis by relieving oxidative stress and modulating the apoptotic process |
|
| ||
| Salvianolic acid B [ | Human neuroblastoma SH-SY5Y cells | Prevents dopamine-induced apoptosis that may be mediated by the ROS and the Erk and Bcl-2 pathways |
Figure 3Schematic diagram of effects of Salvia miltiorrhiza on reactive oxygen species-related apoptosis of cancer cells.
Figure 2Schematic diagram of ROS-related anticancer effects mediated by Danshen. Upregulation: TNF-α, caspase-3, caspase-8, caspase-9, endoplasmic reticulum (ER) stress, P21, P53, Bax/Bcl-2, DR5, AMP-activated protein kinase, MAPK signaling pathways, the phosphorylation (activation) of p38/JNK signaling, and the FasL signaling pathway. Downregulation: hTERT mRNA, telomerase, survivin, VEGF/VEGFR2, CD31, NF-κB, Erk1/2, MMP, microtubule assembly, tyrosine kinases such as EGFR/HER2, P-glycoprotein, and PI3K/Akt/mTOR, and estrogen receptor signaling.